References
- Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364:1046–1060.
- Howlader N, Noone AM, Krapcho M. SEER Cancer Statistics Review, 1975-2009 (vintage 2009 populations). Bethesda, MD: National Cancer Institute; 2012.
- Kumar SK, Rajkumar SV, Dispenzieri A, et al. Survival in multiple myeloma and the impact of novel therapies. Blood 2008;111: 2516–2520.
- Mateos MV. How to maintain patients on long-term therapy: understanding the profile and kinetics of adverse events. Leuk Res 2012;36(Suppl. 1):S35–S43.
- Ludwig H, Sonneveld P. Disease control in patients with relapsed and/or refractory multiple myeloma: what is the optimal duration of therapy? Leuk Res 2012;36(Suppl. 1):S27–S34.
- Lonial S. Relapsed multiple myeloma. Hematology Am Soc Hematol Educ Program 2010:303–309.
- Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011;117:4691–4695.
- van de Donk NW, Görgün G, Groen RW, et al. Lenalidomide for the treatment of relapsed and refractory multiple myeloma. Cancer Manag Res 2012;4:253–268.
- Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenali-domide in hematological malignancies. J Hematol Oncol 2009;2:36.
- Rajkumar SV, Jacobus S, Callander NS, et al. Eastern Cooperative Oncology Group. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomized controlled trial. Lancet Oncol 2010;11:29–37.
- Weber DM, Chen C, Niesvizky R, et al.; Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357: 1738–1744.
- Dimopoulos M, Spencer A, Attal M, et al.; Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123–2132.
- San Miguel JF, Dimopoulos MA, Stadtmauer EA, et al. Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Clin Lymphoma Myeloma Leuk 2011;11:38–43.
- Harousseau JL, Dimopoulos MA, Wang M, et al. Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica 2010;95:1738–1744.
- Lonial S, Knight R, Dimopoulos M, et al. Effect of Len/Dex in MM in different age groups. Haematologica 2007;92(Suppl. 2): Abstract PO–663.
- Touzeau C, Blin N, Clavert A, et al. Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myeloma. Leuk Lymphoma 2012;53:1318–1320.
- Stadtmauer EA, Weber DM, Niesvizky R, et al. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. Eur J Haematol 2009;82:426–432.
- Dimopoulos MA, Palumbo A, Attal M, et al.; European Myeloma Network. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. Leukemia 2011;25:749–760.